Following a recent peer-reviewed publication describing the use of C-Stem™ for massive stem cell expansion, Maxime Feyeux, PhD, co-founder and Chief Scientific Officer of TreeFrog Therapeutics, highlights the bottlenecks that have been solved since the initial submission of the paper, together with future developments.

Following a recent peer-reviewed publication describing the use of C-Stem™ for massive stem cell expansion, Maxime Feyeux, PhD, co-founder and Chief Scientific Officer of TreeFrog Therapeutics, highlights how this platform can impact the manufacturing of stem-cell-derived therapies.

Following a recent peer-reviewed publication describing massive hiPSC expansion in 10L bioreactors with the C-Stem™ technology, Maxime Feyeux, PhD, co-founder and Chief Scientific Officer of TreeFrog Therapeutics, provides insights into iPS differentiation in C-Stem™.

Following a recent peer-reviewed publication describing C-Stem™ – a high-throughput cell encapsulation technology allowing for the massive expansion of pluripotent stem cells in stirred-tank bioreactors, Maxime Feyeux, PhD, co-founder and Chief Scientific Officer of TreeFrog Therapeutics, comes back on the benefits of the capsule.

Following a recent peer-reviewed publication describing the expansion of an iPS cell line in C-Stem™ while maintaining the same genomic profile, Maxime Feyeux, PhD, co-founder and Chief Scientific Officer of TreeFrog Therapeutics, explains how such maintenance of genomic integrity is possible in C-Stem™.

Following a recent peer-reviewed publication describing a 275-fold amplification of human induced pluripotent stem cells (hiPSC) in a 10L bioreactors in 6.59 days with the C-Stem™ technology, Maxime Feyeux, PhD, co-founder and Chief Scientific Officer of TreeFrog Therapeutics, explains how such exponential growth can be obtained.

Is the FDA adapting to cell therapies ? How ? Why and how cell therapy differ from small molecules ? A quick overview with Neil Sheppard, D.Phil, Adjunct Associate Professor in the Department of Pathology & Laboratory Medicine, and Head of the T Cell Engineering Lab (TCEL), at the Center for Cellular Immunotherapies (CCI) at the University of Pennsylvania

What’s the medical need for allogeneic anti-tumor therapies ? What are the challenges of allogeneic modalities in solid tumors ? Neil Sheppard, D.Phil, Adjunct Associate Professor in the Department of Pathology & Laboratory Medicine, and Head of the T Cell Engineering Lab (TCEL), at the Center for Cellular Immunotherapies (CCI) at the University of Pennsylvania has a 20-year experience in the field of immunotherapies and vaccines.

While solid tumors represent the vast majority of cancers, most commercial cell therapies target hematological malignancies. Why ? What are the most promising T cell-based strategies in solid tumors ? A discussion with Neil Sheppard, D.Phil, Adjunct Associate Professor in the Department of Pathology & Laboratory Medicine, and Head of the T Cell Engineering Lab (TCEL), at the Center for Cellular Immunotherapies (CCI) at the University of Pennsylvania has a 20-year experience in the field of immunotherapies and vaccines.

In which cases could allogeneic strategies be used instead of autologous products? What are the most promising clinical trials? A quick overview with Neil Sheppard, D.Phil, Adjunct Associate Professor in the Department of Pathology & Laboratory Medicine, and Head of the T Cell Engineering Lab (TCEL), at the Center for Cellular Immunotherapies (CCI) at the University of Pennsylvania.

Neil Sheppard, D.Phil, Adjunct Associate Professor in the Department of Pathology & Laboratory Medicine, and Head of the T Cell Engineering Lab (TCEL), at the Center for Cellular Immunotherapies (CCI) at the University of Pennsylvania has a 20-year experience in the field of immunotherapies and vaccines. Why is there so much interest in NK cell therapies within the biotech industry ? What is there mode of action in comparison to T cells ? What’s their safety profile ?

Neil Sheppard, D.Phil, Adjunct Associate Professor in the Department of Pathology & Laboratory Medicine, and Head of the T Cell Engineering Lab (TCEL), at the Center for Cellular Immunotherapies (CCI) at the University of Pennsylvania has a 20-year experience in the field of immunotherapies and vaccines. In this interview, he highlights the difference cell sources available to make allogeneic NK and T cells, the related manufacturing challenges, as well recent clinical results with such products.

Miriam Merad, MD, PhD, Oncologist and Director of the Precision Immunology Institute at Mount Sinai in New-York is an expert of tissue-resident immune cells in cancer. Here she highlights the ambivalent role of these cells in cancer and the potential therapeutic strategies to harness them.

Do tissue-resident immune cells constitute a critical cellular compartment, that needs to be taken into account, in any disease ? The point of view of Miriam Merad, MD, PhD, Oncologist, Professor in immunology, Director of the Precision Immunology Institute at Mount Sinai in New-York, and Member of the US National Academy of Science.

Miriam Merad, MD, PhD, Oncologist and Director of the Precision Immunology Institute at Mount Sinai in New-York is an expert of tissue-resident immune cells. Here, she comes back on her discovery of a lineage of tissue-resident macrophages, which is independent of the monocyte lineage, and which may play a critical role in tissue homeostasis.

Miriam Merad, MD, PhD, Director of the Precision Immunology Institute at Mount Sinai in New-York is an expert of tissue-resident immune cells. Here she highlights her discovery of the role of tissue-resident macrophages in Alzheimer’s disease.

Miriam Merad, MD, PhD, Oncologist and Director of the Precision Immunology Institute at Mount Sinai in New-York is an expert of tissue-resident immune cells in cancer. Here she highlights the rationale behind strategies targeting macrophages and dendritic cells with the aim of enhancing CAR-T and NK cells anti-tumor activity.

Miriam Merad, MD, PhD, Oncologist and Director of the Precision Immunology Institute at Mount Sinai in New-York is an expert of tissue-resident immune cells in cancer. With the rise of therapeutic initiatives based on CAR-macrophages, we asked her about this emerging field and the specific challenges of CAR-macrophages.

Miriam Merad, MD, PhD, Oncologist and Director of the Precision Immunology Institute at Mount Sinai in New-York is an expert of tissue-resident immune cells in cancer. Here, she discusses how the reprogrammation of these cells (macrophages, dendritic cells, …) could be used as a therapeutic modality in immuno-oncology.

With a 20-year experience in cancer immunotherapies, Neil Sheppard, comes back on the early days of CAR-T cell therapies, talking about Novartis, U. Penn, Juno, Kite, …

Developmental biologist Marta Shahbazi, group leader at the MRC Laboratory of Molecular Biology in Cambridge, UK, explains how the 3D organization of cells positively impacts cell division, reducing mitotic errors and genomic alterations.

Working with biomimetic 3D cultures of pluripotent stem cells, Developmental biologist Marta Shahbazi, group leader at the MRC Laboratory of Molecular Biology in Cambridge, UK, discusses how mimicking the 3D in vivo organization of cells reduces variability accross pluripotent cell lines and improves cell culture reproducibility.

Working with biomimetic 3D cultures of pluripotent stem cells, Developmental biologist Marta Shahbazi, group leader at the MRC Laboratory of Molecular Biology in Cambridge, UK, discusses how mimicking the 3D in vivo organization of cells reduces variability accross pluripotent cell lines and improves cell culture reproducibility.

Developmental biologist Marta Shahbazi, group leader at the MRC Laboratory of Molecular Biology in Cambridge, UK, explains what has changed since Yamanaka’s Nobel Prize in the field of pluripotent stem cells in terms of technology and applications.